Details:
Under the agreement, Amring granted to Pierre Fabre an exclusive license to exploit and commercialize LYSTEDA (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB) in Mexico.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Lysteda
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Amring Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 29, 2021
Details:
HRA is one of the fastest growing over-the-counter ("OTC") companies globally, with three category-leading self-care brands in blister care (Compeed®), women's health (ellaOne®) and scar care (Mederma®).
Lead Product(s): Ulipristal Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: ellaOne
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Perrigo Company plc
Deal Size: Undisclosed Upfront Cash: $2,100.0 million
Deal Type: Acquisition September 08, 2021